Mr Truman is on strike until we breach £4. |
I miss the good old days. News on a big contract would help! |
Unfortunately Tuco, the company doesn't give us anything to 'talk' about! |
Is it Sunday ?
Tuco. |
No problem Jasie, I'm off to chapel in the morning! No good getting older!!! Best wishes young man. |
Looks like Harry has also suspended his buying program......... |
Gareth 8475
It appears to be as far as I'm concerned!!
I was convinced it was Friday yesterday! |
No order book trades until past 2pm. How very strange! |
3,900 buy 7,500 sell! |
What's happening no trades |
Well we finished up (slightly) on a Friday, I will take that!! News all looks positive to my untrained eye.
Marcus: 8453
I guess most of us on here are now associated with the EDL according to our leader! I don't trust him an inch and time will show just how painful a left wing government can be to the hard working, honest and true people of this country.
Enjoy your sabbatical Harry, see you on the other side!
Have a great weekend all! |
RBC
short-term target of 740p will do nicely. |
Just on the cash balance/burn rate, what we don't know is how much working capital is being soaked up in the order ramp up/acceleration (and ABL business). The cash balance at year end seemed to be bolstered by a reduction in working capital. |
Solid update.If the market was to apply something near average industry ratios,the OXB share price would double to around £7. |
There you go pharmaboy. #8451/2 I promised you, didn't I. |
takeiteasy,
I've written what I think for today now.
At some point we find out what Serum want the 10 year MSA deal for and who the recently signed commercial supply CAR-T deal is with. Both those would be huge news for OXB and the type of news the market is waiting for.
We know there is other stuff too, but I've had enough now for a while and so intend to have one of my irregular sabbaticals until the genuinely interesting news comes - which might not be before the interims.
Until then someone else can have a go at being the straight man for the thread comedian. |
so Harry lacklustre share price impact expected then ... |
My guess here (just a guess) was that they gave a full year presentation without mentioning a quarterly update because they didn't see the need.
Then when Phil and a few others asked where the KPI table was (which we still haven't seen) they felt obliged to put something out, then realised that they had told us a lot of it already.
I wouldn't worry about it. I believe RBC put our a positive flash note this morning to accompany the RNS, which reaffirmed their short-term target of 740p.
News of the CAR-T, Malaria or something similar will almost certainly get them there. When? Why couldn't they buy after the results? We will find out in time. Meanwhile, the snipers will do what they do best. |
why is the secrecy from the end customerbiopharma so vital - any ideas Harry |
I can't really see that a very similar report could not have been released some weeks ago which would have aligned better with their stated timing intentions. Were they hoping that something more substantial was imminent but it has not transpired?
Not that there is anything negative about it, just that the delay fuels speculation. |
 Mentioned previously, but the problem with being generous at the FY results (with post period figures / updates 4 months later) means that there wasn't an awful lot new there with which to excite the market. All the important stuff was as previously mentioned (re growth, projections and such simply reiterated).
They have told us before (a lot) that it was initially going to cost 10m Euros to turn ABL Europe into OXB Europe and that ABL were paying it, but that 10m Euro cost, even though it's paid by them, is still on our books at the end of the year.
Some cash has obviously gone somewhere. They mention staff (and we have seen the ads) but we also know from last year that the first part of turning OXB Boston from AAV into a LentiVector hub for the US cost us nearly 6m (which of course comes out of our cash). That has obviously continued and comes under the category of "it is what it is" as you have to spend money to earn money. If it eventually brings in one "good" Novartis style job there in that location, then that's the money back (and more).
Cash of £103.7m at 31 December 2023
£81 million cash as of 30 June 2024 (this includes the proceeds from a EUR 20 million (£16.9 million) investment by TSGH SAS).
Isn't that £39.6m over the first half or £1.5m per week? We of course know what that is about and we also know that they are profitmaking in H2, but the market will still look at that cash burn simply as a figure and look no further for the explanation.
I'm pretty convinced in myself now that they are keeping Yarnton beyond the lease expiry date this year. That's of course good and bad. Good that they have so much work they need to do it / bad that with the remaining part of OxBox not yet complete, we are paying a lease at Yarnton plus a load of duplicated costs which theoretically they shouldn't have needed to do. Something else under the category of "it is what it is".
They have reissued guidance and that's great and I'm at peace, but there was very little there which we either didn't know or couldn't have taken a good guess at.
We knew there was capex in France and the USA (Stuart told us) and we knew they were having to recruit (we have seen the ads). We knew they would turn to profitability in H2 but that H1 would weigh them down for the full year.
What I was hoping for was news of who the new multiple myeloma commercial CAR-T deal is with - especially as that's very likely the deal which tips us into profit for H2.
As Plutonian has pointed out, if it is a genuinely new company to OXB then it can only really be CARVYKTI (ciltacabtagene autoleucel), Janssen / J&J’s drug.
Tiny chance that it is the BMS drug Abecma (idecabtagene vicleucel) which they bought Celgene to get and OXB are saying Celgene is the new partner (rather than BMS who own them).
OXB almost certainly want to say (hence the clues from them) but have been told they can't. Those are the only 2 options though and either is worth a fortune to OXB. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
